File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Autologous stem cell transplantation for nasal NK/T-cell lymphoma: A progress report on its value

TitleAutologous stem cell transplantation for nasal NK/T-cell lymphoma: A progress report on its value
Authors
KeywordsAutologous stem cell transplantation
Nasal NK/T lymphoma
Issue Date2003
PublisherOxford University Press. The Journal's web site is located at http://annonc.oxfordjournals.org/
Citation
Annals Of Oncology, 2003, v. 14 n. 11, p. 1673-1676 How to Cite?
AbstractNasal NK/T-cell lymphoma is an Epstein-Barr virus-related, highly aggressive but localized disease in Orientals. The median survival is <1 year. Here, we update our experience on 18 patients treated with autologous stem cell transplantation (ASCT). Two patients died of mucositis and septicemia during ASCT. Relapse occurred in nine cases, including six local relapses. Compared with patients treated in remission, all patients treated in active or disseminated disease died of early relapse. Within this cohort, there was no significant survival difference between patients treated in first (CRI, n = 7) or second (CR2, n = 5) complete remissions. However, among consecutive cases analyzed, the patients receiving ASCT at CR1 showed a trend towards better overall survival compared with historical matched controls (P = 0.064). Disease relapse beyond 6 months was not seen after ASCT. Our retrospective data suggest that ASCT in CR1 is a viable consolidation therapy for local-stage NK/T lymphoma, but a randomized trial is needed to prove any definite survival benefit. For patients with relapsed, refractory or extranasal disease, early consideration for allogeneic transplantation and alternative therapy may be warranted.
Persistent Identifierhttp://hdl.handle.net/10722/78583
ISSN
2023 Impact Factor: 56.7
2023 SCImago Journal Rankings: 13.942
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorAu, WYen_HK
dc.contributor.authorLie, AKWen_HK
dc.contributor.authorLiang, Ren_HK
dc.contributor.authorKwong, YLen_HK
dc.contributor.authorYau, CCen_HK
dc.contributor.authorCheung, MMCen_HK
dc.contributor.authorNgan, KCen_HK
dc.contributor.authorLau, WHen_HK
dc.contributor.authorWong, KHen_HK
dc.contributor.authorYiu, HYen_HK
dc.contributor.authorCheng, HCen_HK
dc.contributor.authorAu, KHen_HK
dc.contributor.authorChan, JKCen_HK
dc.date.accessioned2010-09-06T07:44:28Z-
dc.date.available2010-09-06T07:44:28Z-
dc.date.issued2003en_HK
dc.identifier.citationAnnals Of Oncology, 2003, v. 14 n. 11, p. 1673-1676en_HK
dc.identifier.issn0923-7534en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78583-
dc.description.abstractNasal NK/T-cell lymphoma is an Epstein-Barr virus-related, highly aggressive but localized disease in Orientals. The median survival is <1 year. Here, we update our experience on 18 patients treated with autologous stem cell transplantation (ASCT). Two patients died of mucositis and septicemia during ASCT. Relapse occurred in nine cases, including six local relapses. Compared with patients treated in remission, all patients treated in active or disseminated disease died of early relapse. Within this cohort, there was no significant survival difference between patients treated in first (CRI, n = 7) or second (CR2, n = 5) complete remissions. However, among consecutive cases analyzed, the patients receiving ASCT at CR1 showed a trend towards better overall survival compared with historical matched controls (P = 0.064). Disease relapse beyond 6 months was not seen after ASCT. Our retrospective data suggest that ASCT in CR1 is a viable consolidation therapy for local-stage NK/T lymphoma, but a randomized trial is needed to prove any definite survival benefit. For patients with relapsed, refractory or extranasal disease, early consideration for allogeneic transplantation and alternative therapy may be warranted.en_HK
dc.languageengen_HK
dc.publisherOxford University Press. The Journal's web site is located at http://annonc.oxfordjournals.org/en_HK
dc.relation.ispartofAnnals of Oncologyen_HK
dc.rightsAnnals of Oncology. Copyright © Oxford University Press.en_HK
dc.subjectAutologous stem cell transplantation-
dc.subjectNasal NK/T lymphoma-
dc.subject.meshAdulten_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshKiller Cells, Naturalen_HK
dc.subject.meshLymphoma, T-Cell - therapyen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshNeoplasm Recurrence, Localen_HK
dc.subject.meshNose Neoplasms - therapyen_HK
dc.subject.meshRetrospective Studiesen_HK
dc.subject.meshStem Cell Transplantation - adverse effectsen_HK
dc.subject.meshSurvival Analysisen_HK
dc.subject.meshTransplantation, Autologousen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titleAutologous stem cell transplantation for nasal NK/T-cell lymphoma: A progress report on its valueen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0923-7534&volume=14&spage=1673&epage=1676&date=2003&atitle=Autologous+stem+cell+transplantation+for+nasal+NK/T-cell+lymphoma:+a+progress+report+on+its+valueen_HK
dc.identifier.emailLiang, R:rliang@hku.hken_HK
dc.identifier.emailKwong, YL:ylkwong@hku.hken_HK
dc.identifier.authorityLiang, R=rp00345en_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1093/annonc/mdg458en_HK
dc.identifier.pmid14581277-
dc.identifier.scopuseid_2-s2.0-10744225287en_HK
dc.identifier.hkuros87667en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-10744225287&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume14en_HK
dc.identifier.issue11en_HK
dc.identifier.spage1673en_HK
dc.identifier.epage1676en_HK
dc.identifier.isiWOS:000186411000013-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridAu, WY=7202383089en_HK
dc.identifier.scopusauthoridLie, AKW=24284842400en_HK
dc.identifier.scopusauthoridLiang, R=26643224900en_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK
dc.identifier.scopusauthoridYau, CC=7007038422en_HK
dc.identifier.scopusauthoridCheung, MMC=8751688300en_HK
dc.identifier.scopusauthoridNgan, KC=7005884937en_HK
dc.identifier.scopusauthoridLau, WH=7402933278en_HK
dc.identifier.scopusauthoridWong, KH=35097874900en_HK
dc.identifier.scopusauthoridYiu, HY=8364049900en_HK
dc.identifier.scopusauthoridCheng, HC=7404285241en_HK
dc.identifier.scopusauthoridAu, KH=41661035800en_HK
dc.identifier.scopusauthoridChan, JKC=7403287069en_HK
dc.identifier.issnl0923-7534-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats